Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.

Poly-ADP-ribosyl polymerase (PARP) enzymes PARP-1 and PARP-2 recognize DNA damage and set off a cascade of cellular mechanisms required for multiple types of DNA damage repair. PARP inhibitors are small molecule mimetics of nicotinamide which bind to PARP's catalytic domain to inhibit poly-ADP-ribosylation (PARylation) of target proteins, including PARP-1 itself. PARP inhibitors olaparib, veliparib, talazoparib, niraparib and rucaparib have predominantly been studied in women with breast or ovarian cancers associated with deleterious germline mutations in BRCA1 and BRCA2 (gBRCA1/2+). The BRCA1 and BRCA2 proteins are involved in DNA repair by homologous recombination. This review will focus on talazoparib, a PARP inhibitor approved by the US FDA for the treatment of metastatic gBRCA1/2+ breast cancers in October 2018.

• Publication year

  2019

• Venue

  Future Oncology

• Publication date

  2019-03-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon-2018-0751PMID 30912451
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.

  2018cited by this paper
• Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

  2018cited by this paper
• Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

  2018cited by this paper
• Advances in the use of PARP inhibitor therapy for breast cancer

  2018cited by this paper
• A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity

  2017cited by this paper
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  2017cited by this paper
• Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer

  2017cited by this paper
• A feasibility study of neoadjuvant talazoparib for early-stage breast cancer patients with a germline BRCA pathogenic variant: NCT02282345.

  2017cited by this paper
• Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).

  2017cited by this paper
• Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study

  2017cited by this paper
• Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.

  2017cited by this paper
• Replication Fork Reversal: Players and Guardians.

  2017cited by this paper
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

  2016cited by this paper
• Reply to the letter to the editor 'Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients' by Krawczyk et al.

  2016cited by this paper
• Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

  2016cited by this paper
• Phase I/II study of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162).

  2016cited by this paper
• Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.

  2016cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Phase III randomized, placebo-controlled trial of carboplatin (C) and paclitaxel (P) with/without veliparib (ABT-888) in HER2- BRCA-associated locally advanced or metastatic breast cancer (BC).

  2015cited by this paper
• Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

  2015cited by this paper
• Poly(ADP-ribose): a signaling molecule in different paradigms of cell death.

  2014cited by this paper
• Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

  2014cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

  2014cited by this paper
• Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast cancer (BRCA-wt).

  2014cited by this paper
• From polypharmacology to target specificity: the case of PARP inhibitors.

  2013cited by this paper
• Causes and consequences of replication stress

  2013cited by this paper
• Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

  2013cited by this paper
• Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  2013cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

  2012cited by this paper
• The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

  2012cited by this paper
• Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• PARP target practice

  2012cited by this paper
• Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor

  2011cited by this paper
• BRCA1 and BRCA2: different roles in a common pathway of genome protection

  2011cited by this paper
• BRCA mutations in the management of breast cancer: the state of the art

  2010cited by this paper
• Poly(ADP-ribose): novel functions for an old molecule

  2006cited by this paper
• Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal.

  2005cited by this paper
• PARP goes transcription.

  2003cited by this paper
• Cancer susceptibility and the functions of BRCA1 and BRCA2.

  2002cited by this paper
• Review Cancer Susceptibility and the Functions of BRCA1 and BRCA2

  2002cited by this paper
• Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer

  1997cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper

• A Narrative Review on Breast Cancer Treatment Supported by Focused and Systemic Phytotherapy

  2025cites this paper
• Targeting DNA damage response to enhance cancer immunotherapy efficacy: molecular mechanisms and clinical advances

  2025cites this paper
• ALYREF condensation stabilizes m5C-modified PARP10 mRNA and promotes PI3K-AKT signaling in ovarian cancer

  2025cites this paper
• Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy

  2025cites this paper
• Recent Progress in Poly(ADP–Ribose) Polymerase‐1 Inhibitors for Application in Cancer

  2025cites this paper
• Antibody and siRNA Nanocarriers to Suppress Wnt Signaling, Tumor Growth, and Lung Metastasis in Triple‐Negative Breast Cancer

  2024cites this paper
• In silico screening and identifying phytoconstituents of Withania somnifera as potent inhibitors of BRCA1 mutants: A therapeutic against breast cancer.

  2024cites this paper
• Signal Passageway of Phenolic Acid in Opposition to Malignancy Management

  2023cites this paper
• Targeting Breast Cancer: An Overlook on Current Strategies

  2023cites this paper
• Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review

  2022cites this paper
• Triple negative breast cancer: approved treatment options and their mechanisms of action

  2022influential citation
• Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase

  2022cites this paper
• Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson’s Disease

  2021cites this paper
• Oxidative stress and regulated cell death in Parkinson's disease.

  2021cites this paper
• PARP Traps Rescue the Pro-Inflammatory Response of Human Macrophages in the In Vitro Model of LPS-Induced Tolerance

  2021cites this paper
• A novel predicted ADP-ribosyltransferase-like family conserved in eukaryotic evolution

  2021cites this paper
• PARkinson's: From cellular mechanisms to potential therapeutics.

  2021cites this paper
• Bioactive Cationic Peptides as Potential Agents for Breast Cancer Treatment.

  2021cites this paper
• Bioactive cationic peptides as potential agents for breast cancer treatment

  2021cites this paper
• BRCA Mutational Status is a Promising Predictive Biomarker for Platinum-based Chemotherapy in Triple-Negative Breast Cancer.

  2020cites this paper
• Novel Approaches to Target Mutant FLT3 Leukaemia

  2020cites this paper
• DNMT1: A key drug target in triple-negative breast cancer

  2020cites this paper
• PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation

  2020cites this paper
• PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis

  2020cites this paper
• A novel predicted ADP-ribosyltransferase family conserved in eukaryotic evolution

  2020cites this paper
• Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

  2020cites this paper
• PARP-inhibitors in a non‐oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open

  2020cites this paper
• Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods

  2020cites this paper
• DNMT1: A Key Drug Target in Triple-Negative Breast Cancer.

  2020cites this paper
• Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases.

  2020cites this paper
• Natural Products and Synthetic Analogs as a Source of Antitumor Drugs

  2019cites this paper
• Synthesis and cytotoxic activity of chalcone analogues containing a thieno[2,3-d]pyrimidin-2-yl group as the A-ring or B-ring.

  2019cites this paper
• The spectrum of mutations predisposing to familial breast cancer in Poland

  2019cites this paper
• Advances and perspectives of PARP inhibitors

  2019cites this paper